-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
TMDX:NSD- (USD)
COMMON STOCK | Medical Devices |
Last Closing
USD 144.66Change
-1.32 (-0.90)%Market Cap
USD 4.74BVolume
0.45MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Devices |
Last Closing
USD 144.66Change
-1.32 (-0.90)%Market Cap
USD 4.74BVolume
0.45MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
DXCM | DexCom Inc |
N/A |
USD 46.18B |
ALGN | Align Technology Inc |
N/A |
USD 17.85B |
PODD | Insulet Corporation |
N/A |
USD 13.96B |
BRKR | Bruker Corporation |
N/A |
USD 10.11B |
MASI | Masimo Corporation |
N/A |
USD 7.22B |
PRCT | Procept Biorobotics Corp |
N/A |
USD 3.54B |
AXNX | Axonics Modulation Technologie.. |
N/A |
USD 3.45B |
IRTC | iRhythm Technologies Inc |
N/A |
USD 3.09B |
LIVN | LivaNova PLC |
N/A |
USD 2.93B |
TNDM | Tandem Diabetes Care Inc |
N/A |
USD 2.78B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
CYBG:LSE | VanEck Bionic Engineering.. | 4.12 % | 0.00 % |
N/A |
USD 6.25M |
CIB0:XETRA | VanEck Bionic Engineering.. | 3.81 % | 0.00 % |
N/A |
USD 6.26M |
MMSC | First Trust Multi-Manager.. | 1.45 % | 0.00 % |
N/A |
USD 0.02B |
QQQS | Invesco NASDAQ Future Gen.. | 0.89 % | 0.00 % |
N/A |
USD 8.10M |
FFTY | Innovator IBD® 50 ETF | 0.00 % | 0.80 % |
N/A |
USD 0.09B |
XHE | SPDR® S&P Health Care Eq.. | 0.00 % | 0.35 % |
N/A |
USD 0.25B |
Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 83.28% | 93% | A | 95% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 83.28% | 93% | A | 95% | A | ||
Trailing 12 Months | |||||||
Capital Gain | 68.46% | 93% | A | 93% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 68.46% | 93% | A | 93% | A | ||
Trailing 5 Years | |||||||
Capital Gain | 399.00% | 98% | N/A | 95% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 399.00% | 98% | N/A | 95% | A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 65.22% | 92% | A | 93% | A | ||
Dividend Return | 65.22% | 92% | A | 93% | A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 92.83% | 34% | F | 17% | F | ||
Risk Adjusted Return | 70.25% | 97% | N/A | 89% | A- | ||
Market Capitalization | 4.74B | 95% | A | 88% | B+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.